Loading stock data…
ARMK
$44.95-0.74 (-1.62%)
Pre-Market$44.81-0.14 (-0.31%)· Last close May 1
Aramark provides food and facilities services to education, healthcare, business and industry, sports, leisure, and corrections clients in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aramark in the Industrials sector is trading at $44.95. The stock is currently near its 52-week high of $46.88, remaining 13.5% above its 200-day moving average. Technical signals show neutral RSI of 61 and bearish MACD signal, explaining why ARMK maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 61) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$44.95
Potential Downside
48.7%
Whystock Fair Value$23.08
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Aramark provides food and facilities services to education, healthcare, business and industry, sports, leisure, and corrections clients in the United States and internationally. The company operates in two segments, Food and Support Services United S...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.17B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
38.91
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.14
Div Yield
Strong income play. Yield provides a meaningful total return floor.
106.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
9.88%
Volume
Today's trading volume
2.26M
Recent News
How Investors May Respond To Aramark (ARMK) Winning Multi‑Year AI Data Center Services Deal
In April 2026, Aramark announced it had been selected by a top global hyperscaler under a multi-year agreement to provide comprehensive hospitality, housing, and facilities services across multiple AI data center locations in the United States, with revenue starting this fiscal year and delivered through its new Aramark Nexus platform. This marks Aramark’s formal entry into AI data center infrastructure support, leveraging its experience in complex, remote environments to offer an end-to-end...
Is Vestis Corporation (VSTS) A Good Stock To Buy Now?
Is VSTS a good stock to buy? We came across a bullish thesis on Vestis Corporation on Valueinvestorsclub.com by dman976. In this article, we will summarize the bulls’ thesis on VSTS. Vestis Corporation’s share was trading at $9.57 as of April 29th. VSTS’s trailing P/E was 17.49 according to Yahoo Finance. Vestis Corporation (VSTS) is a post-spin […]
3 Cash-Producing Stocks with Warning Signs
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
3 Inflated Stocks with Open Questions
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
How The Aramark (ARMK) Investment Story Is Shifting With New Contracts And 2026 Growth Views
Aramark’s fair value price target has been updated to US$47.16, a slight move from US$47.09 that reflects a modest recalibration rather than a wholesale shift in view. This tweak sits alongside bullish analyst commentary highlighting organic growth, contract wins such as the RWJ Barnabas Health deal, and expectations for sectorwide revenue and cash flow expansion by 2026. As you read on, you will see how these inputs are shaping the evolving analyst narrative and what to watch as it...